Klin Farmakol Farm. 2014;28(3):99-104

Current treatment options for postmenopausal osteoporosis

Pavel Horák, Martina Skácelová
III. interní klinika &ndash, nefrologie, revmatologie, endokrinologie
FN a LF UP Olomouc

Postmenopausal osteoporosis is associated with a significant increase in the risk of fractures. Osteoporotic fractures are associated

with a huge burden for the patient, worsening their functional capacity as well as having a significant economic impact. The primary

or secondary prevention of fractures is the main goal of osteoporosis treatment. Pharmacotherapy plays a major role in the therapy

of postmenopausal osteoporosis. The review paper deals with current treatment options for postmenopausal osteoporosis.

Keywords: postmenopausal osteoporosis, therapy

Published: November 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horák P, Skácelová M. Current treatment options for postmenopausal osteoporosis. Klin Farmakol Farm. 2014;28(3):99-104.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 2000; 11: 669-674. Go to original source... Go to PubMed...
    2. Kanis JA, Johnell O, Oden A, et al. Ten years risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 2002; 30: 251-258. Go to original source... Go to PubMed...
    3. Cauley, JA, Lui LY, Stone KL, et al. Longitudinal study of changes in hip bone mineral density in Caucasian and African-American women. J Am Geriatr Soc; 2005; 53: 183-189. Go to original source... Go to PubMed...
    4. Stěpán JJ, Vaculík J, Pavelka K, et al. Hip fracture incidence from 1981 to 2009 in the Czech Republic as a basis of the country-specific FRAX model. Calcif Tissue Int 2012; 90: 365-372. Go to original source... Go to PubMed...
    5. Dent CE. Keynote address: Problems in metabolic bone disease. In: Frame B. Clinical Aspects of Metabolic Bone Disease. Amsterdam: Excerpta Medica 1973: 1-7.
    6. Žofková I. Měkké tkáně a skelet. In Osteologie a kalcium fosfátový metabolizmus. Grada Publishing a.s., Praha 2012: 66-71.
    7. Cauley JA, Thompson DE, Ensurd KS, et al. Risk of Mortality Following Clinical Fractures. Osteoporosis Int 2000; 11: 556-561. Go to original source... Go to PubMed...
    8. Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis Int 2013; 24: 23-57. Go to original source... Go to PubMed...
    9. Lewiecki EM. Managing osteoporosis, Challenges and strategies. Cleveland Clinical Journal of Medicine 2009; 76: 457-466. Go to original source... Go to PubMed...
    10. Daly RM, Brown M, Bass S, et al. Calcium- and vitamin D3-fortified milk reduces bone loss at clinically relevant skeletal sites in older men, a 2-year randomized controlled trial. J Bone Miner Res 2006; 21: 397-405. Go to original source... Go to PubMed...
    11. Meier C, Woitge HW, Witte K, et al. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss, a randomized controlled open-label prospective trial. J Bone Miner Res 2004; 19: 1221-1230. Go to original source... Go to PubMed...
    12. Jackson RD, La Croix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354: 669-683. Go to original source... Go to PubMed...
    13. Reid IR, Mason B, Horne A, et al. Effects of calcium supplementation on serum lipid concentrations in normal older women, a randomized controlled trial. Am J Med 2002; 112: 343-347. Go to original source... Go to PubMed...
    14. Writing Group for the PEPI. Effects of hormone therapy on bone mineral density, results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996; 276: 1389-1396. Go to original source... Go to PubMed...
    15. National Institutes of Health. Women's Health Initiative. 2003. http://www.nhlbi.nih.gov/whi/.
    16. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis, four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87: 3609-3617. Go to original source... Go to PubMed...
    17. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-1443. Go to original source... Go to PubMed...
    18. Cummings SR, Black DM, Thompson D, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures, results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-2082. Go to original source... Go to PubMed...
    19. Harris ST, Watts NB, Genant HK. Effects of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis, a randomized controlled trial. JAMA 1999; 282: 1344-1352. Go to original source... Go to PubMed...
    20. McClung MR, Geusens P, Miller PD, et al. Hip intervention program study group, effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group. N Engl J Med 2001; 344: 333-340. Go to original source... Go to PubMed...
    21. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis, one-year results from the dosing intravenous administration study. Arthritis Rheum 2006; 54: 1838-1846. Go to original source... Go to PubMed...
    22. Chesnut CH, Skag A, Christiansen C, et al. Effect of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-1249. Go to original source... Go to PubMed...
    23. Delmas PD, Recker RR, Chesnut CH, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk, results from the BONE study. Osteoporosis Int 2004; 15: 792-798. Go to original source... Go to PubMed...
    24. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822. Go to original source... Go to PubMed...
    25. Devogelaer JP, Brown JP, Burckhardt P, et al. Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporosis Int 2007; 18: 1211-1218. Go to original source... Go to PubMed...
    26. Neer RM, Arnaud CD, Zanchetta JR, et al. Effects of parathyroid hormone (1-34) on fractures and bone mineral density of postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1334-1341. Go to original source... Go to PubMed...
    27. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis, a randomized trial. Ann Intern Med 2007; 146: 326-331. Go to original source... Go to PubMed...
    28. Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 2008; 58: 1687-1692. Go to original source... Go to PubMed...
    29. Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int 2000; 11: 83-91. Go to original source... Go to PubMed...
    30. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis, Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 2816-2822. Go to original source... Go to PubMed...
    31. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.